Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zanzalintinib Maintenance in High Grade Neuroendocrine Neoplasms
NCT06926634Phase 2Recruiting
- Sponsor
- Washington University School of Medicine
- Start
- Dec 2025
- Primary completion
- Dec 2034
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of zanzalintinib in Neuroendocrine neoplasm (NEN), sponsored by Washington University School of Medicine. Primary endpoint: Progression-Free Survival up to 6 years. Started Dec 2025; status: recruiting.
02
Drugs
zanzalintinib
03
Conditions
Neuroendocrine neoplasm (NEN)
Beyond the preview
Go deeper on NCT06926634.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06926634.